Event Details

Spark Therapeutics, Inc. at Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting

Monday, May 8, 2017  through Wednesday, May 10, 2017 
Title
Spark Therapeutics, Inc. at Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting
Date / Time
05/08/17
Location
Baltimore Convention Center
  
Description
  • Kathleen Z. Reape, M.D., head of clinical R&D, will present data on the “Natural History of Individuals with Retinal Degeneration Due to Biallelic Mutations in the RPE65 Gene,” on Monday, May 8, from 8:30 to 10:15 p.m. EDT.
  • Daniel C. Chung, D.O., M.A., clinical ophthalmic lead, will present data on the “Correlation of multi-luminance mobility testing with visual function tests in a Phase 3 trial of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease,” on Tuesday, May 9, between 11 a.m. - 12:45 p.m. EDT.
  • Stephen R. Russell, M.D., clinical director of the Stephen A. Wynn Institute for Vision Research, University of Iowa, will present “Year 2 results for a Phase 3 trial of voretigene neparvovec in biallelic RPE65-mediated inherited retinal disease,” on Wednesday, May 10, from 8:30 to 10:15 a.m. EDT.
  • Tomas S. Aleman, M.D., associate professor of ophthalmology at the Perelman School of Medicine, University of Pennsylvania, will present “AAV2-hCHM Subretinal Delivery to the Macula in Choroideremia: Preliminary Six Month Safety Results of an Ongoing Phase I/II Gene Therapy Trial” on Wednesday, May 10, from 11:00 a.m. to 12:45 p.m. EDT.